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Abstract
Background Single large-scale mitochondrial DNA (mtDNA)
deletions (SLSMDs) are amongst the most frequently diag-
nosed mtDNA disorders in childhood, yet their natural history
remains poorly understood. We report the natural history of a
large multicentre cohort of such children.
Methods We reviewed case notes from three different UK
centres to determine the clinical course of 34 patients (16
female, 18 male) with childhood-onset mitochondrial disease
caused by SLSMDs. Kaplan–Meier analysis was used to com-
pare survival of patients presenting with haematological fea-
tures (Pearson syndrome) and those with nonhaematological
presentations.
Results The most frequent initial presentation was with iso-
lated ptosis (16/34, 47 %). Eleven (32 %) patients presented
with transfusion-dependent anaemia soon after birth and were
diagnosed with Pearson syndrome, whilst ten were classified
as having Kearns–Sayre syndrome, three as having progres-
sive external ophthalmoplegia (PEO) and seven as having
PEO-plus. Three patients did not conform to any specific
mitochondrial syndrome. The most frequently affected organ
during the disease course was the kidney, with documented
tubular or glomerular dysfunction in 17 of 20 (85 %) cases
who had detailed investigations. SLSMDs were present in
blood and/or urine cells in all cases tested, indicating that
muscle biopsy is not necessary for diagnosis in the paediatric
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age range. Kaplan–Meier survival analysis revealed signifi-
cantly worse mortality in patients with Pearson syndrome
compared with the rest of the cohort.
Conclusions Mitochondrial disease caused by SLSMDs is
clinically heterogeneous, and not all cases conform to a clas-
sical mitochondrial syndrome. Multisystem disease is the
norm, with anaemia, renal impairment and endocrine distur-
bance being the most frequent extraneurological features.
SLSMDs should be considered in the differential diagnosis
of all children presenting with ptosis.
Background
The overall incidence of mitochondrial disease is uncertain
but has been estimated to be as frequent as 1 in 5,000 births
(Skladal et al. 2003; Schaefer et al. 2004), with single, large-
scale mitochondrial DNA (mtDNA) deletions (SLSMDs) con-
tributing to 10 % of primary mtDNA disorders (Lamont et al.
1998). These deletions tend to occur spontaneously, possibly
arising from defective mtDNA repair mechanisms (Krishnan
et al. 2008) or defective mtDNA replication (Shoffner et al.
1989). In some cases, rearrangements are complex and many
include duplicated mtDNA species (Poulton et al. 1993;
Poulton et al. 1989).
The cornerstone of diagnosis has traditionally been the
recognition of one of the classical phenotypes: Pearson mar-
row–pancreas syndrome, Kearns–Sayre syndrome (KSS),
chronic progressive external ophthalmoplegia (CPEO or
PEO) or (C)PEO-plus. Pearson syndrome was originally de-
fined as a sideroblastic anaemia with associated exocrine
pancreatic dysfunction (Pearson et al. 1979) but is now
recognised as a multisystem mitochondrial disorder in which
the chief feature is sideroblastic anaemia (Manea et al. 2009).
KSS is defined as PEO with pigmentary retinopathy, present-
ing before the age of 20 years, with at least one of these
additional findings: high cerebrospinal fluid (CSF) protein
content, cardiac conduction block or ataxia (Rowland 1983).
Isolated PEO is considered a more benign single-system dis-
order affecting skeletal muscle and is characterised by ptosis,
ophthalmoplegia and variably severe proximal limb weakness
(Biousse and Newman 2001). The term CPEO-plus was
coined by Drachman in 1968 (Drachman 1968) and is now
used to describe patients with PEO who, whilst not fulfilling
the criteria for KSS, havemultisystem involvement (DiMauro
and Hirano 1993). While these clinical phenotypes have been
the mainstay of recognition of SLSMD disorders, increasing
experience has begun to demonstrate considerable overlap
between these syndromes (Pitceathly et al. 2012, Manea
et al. 2009; Yamashita et al. 2008; Grady et al. 2014).
We report a large multicentre paediatric-onset cohort that
demonstrates the clinical overlap of SLSMD disorders pre-
senting in childhood and adds weight to the view that the
apparently distinct Pearson and Kearns–Sayre syndromes
form part of a continuous spectrum of disease (Dimauro
2007; Lopez-Gallardo et al. 2009). Moreover, the findings
reported in our study emphasise the importance of investigat-
ing apparently isolated ptosis presenting in childhood and of a
detailed renal evaluation in all patients with SLSMDs.
Patients and methods
We conducted a multicenter case-notes review of childhood-
onset SLSMDs diagnosed between 1988 and 2011. All patients
diagnosed with symptom onset before age 16 years were
identified through the National Health Service (NHS) Highly
Specialised Services-funded mitochondrial molecular diagnos-
tic laboratories at the National Hospital for Neurology, London,
and the Oxford Radcliffe Hospitals, Oxford. Molecular diag-
nosis of SLSMD was achieved in all cases by Southern blot
and/or long-range polymerase chain reaction (PCR) of DNA
extracted from peripheral blood leukocytes, urinary epithelial
cells or skeletal muscle. All genetic studies were performed
after informed consent from parents/legal guardians of the
patients. Identification of the deletion break point was per-
formed by Sanger sequencing with the use of appropriate
primers where samples were available. Quantitation of mito-
chondrial deletion mutation load compared with the wild type
was determined visually by experienced scientists. This visual
method of quantitation on autoradiographs has been validated
over a number of years by the blinded visual comparison of
deletion load with that found using densitometry (Holt et al.
1989;McShane et al. 1991), and we previously established that
this is associated with an operator error of 5 % compared with
densitometry reading (unpublished observations).
AB or SR reviewed all case notes, and clinical data (includ-
ing symptom onset, multisystem disease features, neuroimag-
ing, muscle histology and histochemistry, blood and CSF bio-
chemistry, respiratory-chain enzyme activities in muscle, genet-
ic data) were collated using a structured pro forma. Statistical
analysis was performed using the SPSS 16 (SPSS forWindows,
Version 16.0. Chicago, IL, USA). The Bonferroni correction
was used for multivariate regression analysis, and Kaplan–
Meier analysis was performed for comparison of survival out-
comes. Statistical significance was set at p <0.05. Ethical ap-
proval for the study was obtained from the National Research
Ethics Committee London, Bloomsbury, UK.
Results
Demographics
Thirty-four patients were identified: 16 female and 18 male.
There was no family history in any case except one set of
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identical twins, patients P and Q, who presented very similar
clinical features (Table 1). Eleven patients were diagnosed with
Pearson syndrome, ten with KSS, three with PEO and seven
with PEO-plus. However, three patients (K, L and R) did not
correspond to any of these classical phenotypes (Table 2). The
details of their initial presentation are shown in Table 1.
Initial presentation
The initial symptoms at presentation are illustrated in Fig. 1.
In 42 % of patients (16 of 34), the first symptom was ptosis,
while haematological manifestations associated with Pearson
syndrome were the second most frequent presenting feature,
Table 1 Demographics and clinical features at presentation
Patient Sex Onset Age at diagnosis Age at death Age at last
review (years)
Birth weight
(kg)
Presenting complaint
A F Birth 1.5 months 5 years 3 months 2.5 Anaemia at birth
B M Birth 2 years 2 months 7 years 5 months 3.46 Poor feeding, then anaemia
C M Birth 7 years 10 months 8.5 3.4 Anaemia at birth
D F Birth 5 months 2 years 6 months 1.6 (Twin 2, 34
weeks’ gestation)
Anaemia at birth
E F Birth 1 months 4 months 1.54 IUGR/pancytopenia/diabetes mellitus/RVH
F M Birth 4 years 8 months 6 3.35 Ptosis + anaemia
G F Birth 2 months 14 months 1.7 (Twin 1, 34
weeks’ gestation)
Anaemia
H M 2 months 13 months 2 years 4 months 3.7 Intermittent dyspnoea + anaemia
I F 5 months 2 years 8 months 4 years 5 months 3 Anaemia
J M 16 months 2 years 6 NA Anaemia
K F 6 months 21 months 16 years 2 months 3.9 Failure to thrive + diarrhoea
L M 2 years 14 years 24 NA Fanconi syndrome + rickets
M M 2 years 6 years 11 years 5 m 2.9 Left-sided ptosis
N F 2 years
6 months
6 years 10 NA Ptosis
O M 3 years 6 years 21 years 3.8 Low appetite/low energy/hyponatraemia
P M 4 years 8 years 12 1.7 (Twin 2) Ptosis at 4 years, adrenal insufficiency
at 5 years
Q M 5 years 8 years 12 2.8 (Twin 1) Adrenal insufficiency investigated after
twin 2’s diagnosis
R M Birth 3 months 1 year 9 months 2.32 Poor feeding, hypoglycaemia, faltering
growth, lactic acidosis
S F 12 years 17 years 25 3.05 Ptosis onset at 12 years
T F 8 years 12 years 12 NA Tremor + migraine at 8 years, ptosis at
12 years
U F 5 years 19 years 19 NA Ptosis
V F 7 years 8 years 20 NA Ptosis
W M 5 years 10 years 15 NA Recurrent inflammation of the eye
X F 15 years 25 years 25 NA Ptosis from early childhood
Y M 14 years 24 years 24 NA Ptosis
Z M 8 years 13 years 13 2.2 Ptosis
AA M 11 years 13 years 13 3.06 Ptosis
AB F 5 years 9 years 15 NA Ptosis
AC M 6 years 13 years 17 3.85 Ptosis
AD F 7 years 12 years 22 NA Ptosis
AE F 7 years 18 years 25 NA Ptosis, then muscular weakness at 14 years
AF M 5 years 8 years 13 2.5 Short stature, poor appetite
AG M 4 months 5 months 2.5 3.96 Anaemia and failure to thrive
AH F 9 years
6 months
11 years 15 2.28 Ptosis
IUGR intrauterine growth restriction, RVH right ventricular hypertrophy, NA not available
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occurring in 32 % (11 of 34). Median age at presentation was
1 week [interquartile range (IQR) 3 months] for these 11
patients, and 6 years (IQR 5 years) for those not diagnosed
with Pearson syndrome.
Survival
Overall, 11 patients died: seven with Pearson syndrome, two
with KSS and two with atypical presentations. Kaplan–Meier
survival analysis (Fig. 2) revealed a significant difference
(p=0.01) in mortality between those with Pearson syn-
drome when compared with the other clinical phenotypes.
Survival at 18 years was 22 % for Pearson syndrome and
73 % for patients with other clinical presentations.
Haematological involvement
Table S1 details the haematological manifestations observed
in the 11 patients diagnosed with Pearson syndrome. Most of
these cases presented soon after birth with transfusion-
Table 2 Genotypic data
Patient Clinical diagnosis Tissue investigated Deletion breakage points (bp) Size (kb) Number of tRNA genes deleted % heteroplasmy
A Pearson Bone marrow Common del (8473→13447) 4.97 5 80
B Pearson Muscle 12102→14113 2.01 3 85
C Pearson Muscle Common del (8473→13447) 4.97 5 90
D Pearson Blood NA 5a NA NA
E Pearson Muscle Common del (8473→13477) 4.97 5 90
F Pearson Blood 7983→13983 6 6 86
G Pearson Blood Common del (8474→13447) 4.97 5 70
H Pearson Blood NA 2.7a NA 70
I Pearson Blood Common del (8473→13446) 4.97 5 70
J Pearson Blood NA >5a NA 50
K Unclassified Blood NA 5.5a NA 50
L Unclassified Blood NA 4.2a NA NA
M KSS Blood NA 7a NA NA
N KSS Blood
Urine
7909→13378 5.46 6 70
85
O KSS Blood NA 3.9a NA
P PEO+ Blood 7771→15406 7.6 7 60
Q PEO+ Blood 7771→15406 7.6 7 60
R Unclassified Blood Common del (8467→13447) 4.96 5 85
S KSS Muscle Common del (8473→13447) 4.97 5 80
T KSS Blood Common del (8482→13477) 4.97 5 NA
U PEO Muscle Common del ((8473→13477) 4.97 5 45
V KSS Blood
Muscle
Common del (8473→13477) 4.97 5 55
45
W KSS Blood Common del (8473→13477) 4.97 5 50
X PEO Muscle Common del (8473→13477) 4.97 5 60
Y PEO+ Muscle Common del (8483→13477) 4.97 5 60
Z KSS Urine Common del (8474→13477) 4.97 5 50
AA PEO+ Blood NA 5a NA NA
AB PEO+ Blood NA 3.6a NA NA
AC KSS Blood NA 7.5a NA 45
AD PEO Muscle NA 4.4a NA 75
AE PEO+ Muscle Common del (8473→13477) 4.97 5 NA
AF KSS Muscle 6133→14092 7.96 11 55
AG Pearson Blood Common del (8473→13477) 5 5 80
AH PEO + Blood NA 5.1a NA 25
del deletion, KSS Kearns–Sayre syndrome, PEO progressive external ophthalmoplegia, PEO + PEO with additional clinical features, NA not available
a Approximate size
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dependent anaemia. Neutropaenia developed in ten patients,
and thrombocytopaenia was documented in eight cases. Bone
marrow aspirates were performed in ten patients; all had
vacuolization of haematopoietic precursors, although classical
ringed sideroblasts were observed in only seven cases. No
evidence of impaired haematopoeisis was documented in the
other 23 patients.
Gastrointestinal and endocrine involvement and growth
Birth weight was <3rd centile in six of 22 patients whose birth
weights were available. It is to be noted that two of these six
patients, D and G, were both born prematurely at 34 weeks;
two patients, B and F, were second babies of twin pregnancies.
The weight of 19 of 30 patients, for whom serial auxologywas
available, fell below the 3rd centile during follow-up
(Table S2).
Four patients with Pearson syndrome had a history of
recurrent diarrhoea, three of whom had reduced faecal elastase
suggesting pancreatic insufficiency (Table S2). Overall, five
of 16 patients tested had reduced faecal elastase, four of whom
fulfilled criteria for classical Pearson syndrome. However,
patient K never had any haematological problems (Morris
et al. 1997). Patient K also developed a severe enteropathy
with marked inflammatory cell infiltrate at age 4 years, neces-
sitating parenteral nutrition for 6 months. Patient M developed
severe abdominal pain, nausea, vomiting and diarrhoea at
10 years and had documented gast ropares is on
electrogastrography and gastric-emptying scintigraphy stud-
ies. Of note, patient E, who had diabetes mellitus but no
symptoms suggestive of malabsorption, had a hypoplastic
pancreas on autopsy.
Endocrine dysfunction was a frequent occurrence: three
patients (P, Q and W) had cortisol deficiency requiring steroid
supplementation, one (A) had hypothyroidism, three (J, W, V)
had hypoparathyroidism and nine had glucose tolerance tests
indicative of diabetes mellitus. Of these nine, two patients (A
and G) had concurrent pancreatic exocrine insufficiency sug-
gesting global pancreatic dysfunction. Patients M, W and AF
were shown to have growth hormone insufficiency and had a
good clinical response to growth hormone supplementation.
Renal disease
Impairment of renal function defined as either a reduction of
glomerular filtration rate (GFR), measured by isotope excre-
tion, or an abnormal elevation of urinary tubulopathy markers
retinol binding protein (RBP) (Bernard et al. 1987) or N-
acetyl-3-glucosaminidase (NAG) (Vaidya et al. 2008), i.e. an
abnormal RBP/creatinine and/or an abnormal NAG/creatinine
ratio, was observed in 14 of 20 patients in whom renal func-
tion had been investigated in detail (Table S3). Five of eight
patients tested had abnormal GFRs, four of whom (A, K, L
andW) also showed elevation of urinary tubulopathy markers
suggesting global impairment of both filtration and tubular
function. Patient K developed end-stage renal failure. Of the
16 patients who had NAG and RBP/creatinine ratios exam-
ined, both were elevated in 13, NAG in two and one was
normal for both. In addition to the 20 patients who had formal
investigations, two (G and H) were deemed likely to have had
a tubulopathy given their combination of aminoaciduria and
Fig. 1 Clinical features at presentation. Initial clinical problems in 34
patients with childhood-onset mitochondrial disease caused by single
large-scale mitochondrial DNA deletions
Fig. 2 Kaplan–Meier survival
graph showing overall survival to
18 years of 34 patients with single
large-scale mitochondrial DNA
deletions, compared with
subgroups with a diagnosis of
Pearson syndrome (n=11) and
those without haematological
involvement. (p<0.001 Mantel–
Cox log-rank test.)
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polyuria; however, this was never formally investigated. Four
of seven renal biopsies were normal histologically despite
severely reduced GFRs in three of these cases, while two
biopsies revealed calcium deposition and the seventh showed
cystic dilatation.
Cardiac function
Cardiac function was assessed using electrocardiogram
(ECG) (29 patients) and echocardiogram (28 patients), and
abnormalities were detected in 13. Rhythm disturbances were
found in nine of the 29 patients examined, including complete
heart block in five (A, N, O, V and AF) at 5, 9, 12, 13 and
8 years, respectively. Patient A had a heart rate of only 20
beats per minute prior to pacing and died 3 weeks after
developing complete heart block (Rahman et al. 2000).
Patient N, alive 26 months after insertion of pacemaker, has
severe cardiomyopathy with inter- and intraventricular
dyssynchrony, dyskinetic ventricular septum and fractional
shortening of 18 % despite high-dose lisinopril therapy. Two
patients (I and W) developed incomplete right bundle branch
block, a known precursor to more severe pathogenic conduc-
tion defects (Riera et al. 2008), having previously had normal
ECGs. Other abnormalities noted included supraventricular
disturbances (Y and L), first-degree block (Z), left ventricular
hypertrophy (LVH) (K and R) and right ventricular hypertro-
phy (RVH) (H).
Neurological features and neuroimaging
The most frequent neurological manifestation was ptosis,
affecting 22 patients, although only nine had frank external
ophthalmoplegia (Table 3). Interestingly, all of those who
presented with ptosis, except patients W and Y, were given
an initial diagnosis of congenital ptosis despite only patient F
being symptomatic before the age of 1 year. Retinal dystrophy
was observed in 13 patients, while patients B, L and W had
corneal thickening, a previously unrecognised manifestation
of SLSMD diseases. A delay in achievement of gross motor
milestones was seen in nine of 34 patients, while 18 had
clinical signs of neurological involvement, including eight
with hypotonia, nine with reduced power and two with ataxia.
Only three patients were reported to have seizures (Table 3).
Ten of 15 patients tested had sensorineural hearing loss,
including patient K who required cochlear implants (Table 3).
Brain magnetic resonance imaging (MRI) was abnormal in
nine (J, K,M, N, Q, R, T, W and AF) of 13 patients examined
(Table 3). In eight cases, the predominant finding was of basal
ganglia changes, but six also had white matter changes, whilst
patient R had changes suggestive of a neuronal migration
defect. Neuroimaging in the four patients (J, M, N and Z)
with low levels of CSF 5-methyltetrahydrofolate (5-MTHF)
revealed white matter lesions in the three severely affected,
but patient Z, whose level was only just below the normal
range, had a normal scan.
Muscle histology and histochemistry
Muscle biopsies were performed in 14 patients and were
abnormal in 12 cases (Table 3). Ragged red fibres were
observed in all 12 abnormal biopsies, whilst cytochrome
oxidase (COX)-negative fibres were seen in 11. Excessive
lipid was observed in seven, while abnormalities in mitochon-
drial morphology on electron microscopy were seen in six.
The two other histologically normal biopsies were both small
samples and in the case of patient K was performed at the
relatively early age of 9 months, while electron microscopy
was not performed in patient H.
Biochemistry
Blood lactate was raised (>2.0 mmol/l) in the majority (21 of
30, 70 %) of patients tested (Table S4). Of the 20 who had
concurrent amino acid profiles performed, 15 had an accom-
panying rise in plasma alanine to 492–889 μmol/L (reference
<450 μmol/l). Plasma alanine was elevated in 15 patients, but
patients M, Q and W had no accompanying rise in lactate.
Raised levels of lactate were noted in the urine of all patients
except W. Patient M also had a raised plasma proline at
323 μmol/L (reference 85–290 μmol/l). Urinary organic acid
analysis revealed an increase in 3-hydroxybutyrate in ten of 17
patients tested, suggestive of a shift in cellular redox potential
to a more reduced state. Two patients (B and R) had raised
levels of tricarboxylic acid cycle metabolites. CSF lactate was
elevated (>1.8 mmol/L) in all ten patients tested. CSF protein
was markedly elevated in all nine patients for whom data was
available, in keeping with a diagnosis of KSS, although one of
these (R) did not fulfil diagnostic criteria for KSS, since there
was no ophthalmoplegia. All four patients who had CSF 5-
MTHF determined had low levels, although two cases (J and
Z) had initial normal values but later had undetectable levels
(at the ages of 6 and 15 years, respectively).
Genetics
Of the 34 patients in this cohort, the diagnosis of SLSMDs was
established in 22 by analysis of blood DNA. Of the other 12,
muscle was analysed in ten and urinary epithelial cells and tissue
obtained from a bonemarrow aspirate in one case each (Table 2).
Breakage points were determined for 22 patients: 12 in blood,
eight in muscle and one each in tissue from a bone marrow
aspirate and urinary tract epithelial cells. Of these 22, 16 had the
common 4.97 kb mtDNA deletion. There was no correlation
between age of presentation and size of deletion in these 22
patients, but there was a statistically significant but weak corre-
lation between per cent of deletion found in tissue and age at
J Inherit Metab Dis
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presentation (p=0.04, R2=0.45.) We observed no correlation
between age at presentation and number of total RNA (tRNA)
genes deleted or MT-CYB deletion in these 22 patients.
Discussion
While Kearns and Sayre’s original clinical description was
published in 1958 and Pearson’s was published in 1979
(Kearns and Sayre 1958; Pearson et al. 1979), knowledge that
mtDNA deletions were responsible was only established in
1988 (Holt et al. 1988). Subsequently, many individual case
reports and case series have been published that increas-
ingly suggest a clinical overlap between these historically
different phenotypes (Manea et al. 2009; Yamashita et al.
2008; Pitceathly et al. 2012; Grady et al. 2014; McShane
et al. 1991).
All 34 patients described here had singlemtDNA deletions:
11 (A–J and AG) presented with varying degrees of anaemia
and haematological dysfunction and fulfilled diagnostic
criteria for the Pearson marrow–pancreas syndrome.
However, pancreatic exocrine dysfunction was only docu-
mented in four: A, B, G and I (Table S2). Even in those with
pancreatic dysfunction, the dysfunction was first documented
at least 2 years after the initial presentation with anaemia,
providing further evidence that the presence of pancreatic
exocrine dysfunction should not be considered as an essential
diagnostic criterion for Pearson syndrome. Our findings are in
agreement with previous observations that one third of
Pearson syndrome patients present solely with anaemia
(Manea et al. 2009), with pancreatic dysfunction at presenta-
tion in only 12.7 % of cases, although this increases to 18 %
by the age of 4 years (Lee et al. 2007). Low birth weight has
previously been reported to be the most common
nonhaematological finding in Pearson syndrome, affecting
up to 63 % of patients (Manea et al. 2009). While at first
glance our cohort might appear to reinforce these observa-
tions, with four of ten being <3rd centile at birth, on closer
examination, two of these patients (D and G) were born
prematurely at 34 weeks’ gestation, while patients D and P
were second twins.
A novel finding of our study is the extent of multisystem
disease in patients with Pearson syndrome (Fig. 3).
Historically, <20 % of patients were reported to have symp-
toms unrelated to bone marrow or gastrointestinal tract
(Manea et al. 2009), but in our cohort, all Pearson syndrome
patients had involvement of other systems. The renal tract was
most commonly involved, with evidence of renal dysfunction
in five Pearson syndrome cases, including Fanconi-type
tubulopathy in two cases (G and H) and profound glomerular
impairment in two (A and C). Renal involvement was not
confined to those children with haematological problems, andTa
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overall, 17 of 20 (85 %) patients for whom results were
available had abnormal glomerular and/or tubular dysfunc-
tion. The majority of patients had proximal tubulopathy, but
other renal manifestations included glomerular compromise
(A, K, L andW), nephrocalcinosis (diagnosed on autopsy in E
and by ultrasound in W). End-stage renal failure occurred in
one patient (K).
Our study demonstrates the relatively high frequency of
renal disease in patients with mtDNA deletions. This is par-
ticularly interesting in light of previous observations of pro-
gressive renal failure in a murine model with mtDNA dele-
tions (Inoue et al. 2000) and validates this model for preclin-
ical trials of novel therapies for mtDNA deletion disorders.
Furthermore, the utility of highly sensitive urinary markers of
tubular damage, NAG and RBP (Herget-Rosenthal et al.
2004; Vaidya et al. 2008), allows presymptomatic detection
of renal involvement and, consequently, early intervention.
The presence of renal tubulopathy as detected by NAG/
creatinine and RBP/creatinine ratios can also be a useful
diagnostic clue and serve to increase clinical suspicion of an
underlying mitochondrial disorder.
Ten of the 23 patients whose presentation was not second-
ary to anaemia fulfilled clinical diagnostic criteria for KSS.
Patients U, X and AD were classified as having PEO and
patients P, Q, Y, AA, AB, AE and AH as PEO+, since ptosis is
recognised to precede ophthalmoplegia by several years
(Jackson et al. 1995). In 15 of the 16 patients with ptosis, it
was the only clinical symptom at initial presentation. Since
SLSMDs can be detected noninvasively in children (on blood
or urine analysis), we recommend that all children >1 year
with undiagnosed new-onset ptosis should be screened for
SLSMDs. It is to be noted, however, that ptosis in patient
F was present at birth, and thus SLSMDs should be considered
even in patients with apparent congenital ptosis, particularly if
other systems subsequently become involved.
Cardiac involvement is well recognised in KSS and report-
ed to affect almost 60 % of cases (Berenberg et al. 1977).
Cardiac manifestations are less well known in Pearson syn-
drome (Rahman and Leonard 2000; Krauch et al. 2002;
Akaike et al. 1997), but we observed cardiac involvement in
three of 11 (27 %) children: two had rhythm disturbances:
patient I, and patient B previously reported by Rahman et al.
(Rahman and Leonard 2000); one (H) had RVH. Cardiac
manifestations in other phenotypic subgroups were two KSS
and three PEO+ patients (all had conduction defects), and
three in the unclassified group (K and R had LVH; L had
atrial fibrillation).
The spectrum of neurological presentations in childhood
SLSMDs is constantly increasing (Morel et al. 2009; Lee et al.
2007). In the study reported here, the major documented
neurological findings were generalised hypotonia and muscle
weakness, with resultant delay in gross motor development in
five patients. Neuromuscular symptoms were more common
in patients without haematological impairment, possibly
reflecting the high mortality rate in patients with Pearson
syndrome, i.e. patients died before onset of neuromuscular
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symptoms. Early mortality of Pearson patients likely also
explains the predominance of brain imaging abnormalities in
patients without bone marrow manifestations. The most fre-
quently observed brain MRI abnormalities were basal ganglia
and white matter lesions. A notable exception was patient R,
who appeared to show signs of impaired neuronal migration.
To our knowledge, this is the first time anmtDNA deletion has
been associated with imaging changes suggestive of a neuro-
nal migration disorder, although other defects of mitochondri-
al oxidative phosphorylation (OXPHOS) function have been
seen in patients with neuronal migration defects (van Straaten
et al. 2005). As previously reported (McShane et al. 1991), we
observed progression from Pearson syndrome to KSS in the
two survivors who had long-term follow up.
Three patients, K, L and R, had no obvious external
ophthalmoplegia or ptosis and, since they also did not have
haematological compromise, fell outside any of the classical
SLSMD phenotypes. They were diagnosed during investiga-
tion for other problems: faltering growth (K), Fanconi syn-
drome (L) and persistent neonatal lactic acidosis (R). Since
patients with multisystem involvement are increasingly being
investigated for mitochondrial disorders, it is likely that in the
future a greater number of children will fall into this ill-
defined group and new phenotypes of SLSMDs will emerge.
The range of clinical phenotypes was reflected in the varied
need for symptomatic support. The need for careful endocri-
nology monitoring is evidenced by the requirement for hor-
mone replacement in 12 of our cases: one required thyroxine,
four cortisol replacement therapy, three vitamin D for hypo-
parathyroidism and three growth hormone. However, as might
be expected, the most common endocrine abnormality was
diabetes mellitus; five of the nine patients with abnormal
glucose tolerance tests required insulin. Patients with impaired
pancreatic exocrine function required pancreatic enzyme re-
placement. The other commonly compromised systems were
cardiac (pacing was required in five patients) and renal: eight
patients needed medical therapy (electrolyte replacement, in
very high doses in some cases), one had renal replacement
therapy while being considered for a transplant and one had
lithotripsy to treat renal calculi. Finally, the importance of
regular audiometry is emphasised by the finding of impaired
hearing in ten patients and the need for cochlear implantation
in one. This degree of multidisciplinary input, with contribu-
tion to management by specialist audiological physicians,
cardiologists, endocrinologists, gastroenterologists,
haematologists, nephrologists, neurologists, ophthalmologists
and palliative care physicians, again emphasises the need for
coordinated care of children with SLSMDs at a tertiary spe-
cialist centre.
Overall, our data provides further support for a clinical
continuum of syndromes associated with SLSMDs manifest-
ing in childhood. However, subdivision into Pearson syn-
drome and KSS may be useful for prognosis, as demonstrated
by survival analysis of this cohort (Fig. 2). Five-year survival
in patients manifesting with a Pearson phenotype was <50 %
from time of initial presentation compared with 100 % for
other phenotypic subgroups (P<0.001). Although this mor-
tality rate is high, it is considerably lower than a historical
report of 76 % 5-year mortality (Rotig et al. 1995).
Interestingly, survival at 4 years was 55 % in a more recent
cohort (Manea et al. 2009), suggesting the possibility that
earlier recognition of Pearson syndrome and intense manage-
ment of known complications may be improving survival
rates. Furthermore, all patients with Pearson syndrome who
survived to 8 years were still alive at 18 years, which may be a
useful prognostic feature when counselling parents and im-
portant information in planning transition to adult services.
Genotype–phenotype correlation for SLSMDs remains
controversial. Traditionally, there was thought to be no rela-
tionship between the length of mtDNA deletion and clinical
phenotype (Lopez-Gallardo et al. 2009; Rotig et al. 1995;
Aure et al. 2007). However more recent work suggests that
location (Lopez-Gallardo et al. 2009; Yamashita et al. 2008)
and number of deleted tRNA molecules (Yamashita et al.
2008) may possibly influence phenotype, and a study of 87
patients (only five of whom presented younger than 20 years)
indicated that mtDNA deletion size was correlated with both
age at onset and progression rate. However, the impact of
deletion size was mediated by the degree of heteroplasmy
seen in muscle biopsy (Grady et al. 2014). It also suggested
that deletion of theMT-CYB gene was associated with a more
severe phenotype. In contrast, in our cohort, we found no
correlation between patient age and deletion size or MT-CYB
deletion. There was a significant, if minor, statistical correla-
tion between degree of heteroplasmy and age at presentation.
However, since quantitation was performed using visual in-
spection, this finding should be interpreted with caution.
Conclusions
This retrospective cohort of patients with childhood-onset
SLSMDs provides further evidence for a continuous clinical
spectrum of disease associated with this genetic defect, in-
cluding the occurrence of atypical presentations. Clinicians
(including general paediatricians, neonatologists, ophthalmol-
ogists, renal physicians, endocrinologists, gastroenterologists,
haematologists, child neurologists and paediatric metabolic
specialists) should be aware of these heterogeneous presenta-
tions and maintain a high degree of suspicion for SLSMDs.
Clinical features that should particularly raise suspicion of
SLSMDs in children include sideroblastic anaemia, ptosis
and multisystem disease with neurological, cardiac, renal
and/or gastrointestinal manifestations. We find no correlation
between deletion size and location and phenotype, but clinical
categorisation into Pearson syndrome, KSS or PEO continues
J Inherit Metab Dis
to be an important tool for prognostication. Longer survival of
Pearson syndrome patients in this cohort compared with his-
torical cohorts emphasises the importance of proactively mon-
itoring for and aggressively managing known multisystem
complications, including cardiac conduction defects, diabetes
mellitus and renal impairment.
Acknowledgments SR and PTC are supported by the Great Ormond
Street Hospital Children’s Charity. The authors thank the audiological
physicians, biochemists, cardiologists, endocrinologists, gastroenterolo-
gists, haematologists, nephrologists, neurologists, ophthalmologists, pal-
liative care physicians and pathologists involved in the diagnosis and
management of these patients. MtDNA breakage points of patient E were
determined in the NSCT mitochondrial laboratory, Newcastle.
Conflict of interest None.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
AkaikeM, Kawai H, Yokoi K et al (1997) Cardiac dysfunction in patients
with chronic progressive external ophthalmoplegia. Clin Cardiol 20:
239–243
Aure K, Ogier de Baulny H, Laforet P et al (2007) Chronic progressive
ophthalmoplegia with large-scale mtDNA rearrangement: can we
predict progression? Brain 130:1516–1524
Berenberg RA, Pellock JM, DiMauro S et al (1977) Lumping or splitting?
“Ophthalmoplegia-plus” or Kearns-Sayre syndrome? AnnNeurol 1:
37–54
Bernard AM, Vyskocil AA, Mahieu P, Lauwerys RR (1987) Assessment
of urinary retinol-binding protein as an index of proximal tubular
injury. Clin Chem 33:775–779
Biousse V, Newman NJ (2001) Neuro-ophthalmology of mitochondrial
diseases. Semin Neurol 21:275–291
Di Mauro S, Hirano M (1993–2014) Mitochondrial DNA deletion syn-
dromes. In: Pagon RA, Adam MP, ardinger HH et al (eds)
Genereview©[Internet]. Seattle(WA):University of Washington, Seattle
Dimauro S (2007) Mitochondrial DNA, medicine. Biosci Rep 27:5–9
Drachman DA (1968) Ophthalmoplegia plus. The neurodegenerative
disorders associated with progressive external ophthalmoplegia.
Arch Neurol 18:654–674
Grady JP, Campbell G, Ratnaike T et al (2014) Disease progression in
patients with single, large-scale mitochondrial DNA deletions. Brain
137:232–34
Herget-Rosenthal S, Poppen D, Husing J et al (2004) Prognostic value of
tubular proteinuria and enzymuria in nonoliguric acute tubular ne-
crosis. Clin Chem 50:552–558
Holt IJ, Harding AE, Morgan-Hughes JA (1988) Deletions of muscle
mitochondrial DNA in patients with mitochondrial myopathies.
Nature 331:717–719
Holt IJ, Harding AE, Cooper JM et al (1989) Mitochondrial myopathies:
clinical and biochemical features of 30 patients with major deletions
of muscle mitochondrial DNA. Ann Neurol 26:699–708
Inoue K, Nakada K, Ogura A et al (2000) Generation of mice with
mitochondrial dysfunction by introducing mouse mtDNA carrying
a deletion into zygotes. Nat Genet 26:176–181
Jackson MJ, Schaefer JA, Johnson MA, Morris AA, Turnbull DM,
Bindoff LA (1995) Presentation and clinical investigation of mito-
chondrial respiratory chain disease. A study of 51 patients. Brain
118(Pt 2):339–357
Kearns TP, Sayre GP (1958) Retinitis pigmentosa, external
ophthalmophegia, and complete heart block: unusual syndromewith
histologic study in one of two cases. AMA Arch Ophthalmol 60:
280–289
Krauch G, Wilichowski E, Schmidt KG, Mayatepek E (2002) Pearson
marrow-pancreas syndrome with worsening cardiac function caused
by pleiotropic rearrangement of mitochondrial DNA. Am J Med
Genet 110:57–61
Krishnan KJ, Reeve AK, Samuels DC et al (2008) What causes
mitochondrial DNA deletions in human cells? Nat Genet 40:
275–279
Lamont PJ, Surtees R, Woodward CE, Leonard JV, Wood NW, Harding
AE (1998) Clinical and laboratory findings in referrals for mito-
chondrial DNA analysis. Arch Dis Child 79:22–27
Lee HF, Lee HJ, Chi CS, Tsai CR, Chang TK, Wang CJ (2007) The
neurological evolution of Pearson syndrome: case report and litera-
ture review. Eur J Paediatr Neurol 11:208–214
Lopez-Gallardo E, Lopez-Perez MJ, Montoya J, Ruiz-Pesini E (2009)
CPEO and KSS differ in the percentage and location of the mtDNA
deletion. Mitochondrion 9:314–317
Manea EM, Leverger G, Bellmann F et al (2009) Pearson syndrome in the
neonatal period: two case reports and review of the literature. J
Pediatr Hematol Oncol 31:947–951
McShaneMA, Hammans SR, SweeneyM et al (1991) Pearson syndrome
and mitochondrial encephalomyopathy in a patient with a deletion
of mtDNA. Am J Hum Genet 48:39–42
Morel AS, Joris N, Meuli R et al (2009) Early neurological impairment
and severe anemia in a newborn with Pearson syndrome. Eur J
Pediatr 168:311–315
Morris AA, Lamont PJ, Clayton PT (1997) Pearson’s syndrome without
marrow involvement. Arch Dis Child 77:56–57
Pearson HA, Lobel JS, Kocoshis SA et al (1979) A new syndrome
of refractory sideroblastic anemia with vacuolization of marrow
precursors and exocrine pancreatic dysfunction. J Pediatr 95:
976–984
Pitceathly RD, Rahman S, Hanna MG (2012) Single deletions in mito-
chondrial DNA–molecular mechanisms and disease phenotypes in
clinical practice. Neuromuscul Disord 22:577–586
Poulton J, Deadman ME, Gardiner RM (1989) Duplications of
mitochondrial DNA in mitochondrial myopathy. Lancet 1:
236–240
Poulton J, Deadman ME, Bindoff L, Morten K, Land J, Brown G (1993)
Families ofmtDNA re-arrangements can be detected in patients with
mtDNA deletions: duplications may be a transient intermediate
form. Hum Mol Genet 2:23–30
Rahman S, Leonard JV (2000) Early onset of complete heart block in
Pearson syndrome. J Inherit Metab Dis 23:753–754
Riera AR, Kaiser E, Levine P et al (2008) Kearns-Sayre syndrome:
electro-vectorcardiographic evolution for left septal fascicular block
of the his bundle. J Electrocardiol 41:675–678
Rotig A, Bourgeron T, Chretien D, Rustin P, Munnich A (1995)
Spectrum of mitochondrial DNA rearrangements in the
Pearson marrow-pancreas syndrome. Hum Mol Genet 4:
1327–1330
Rowland LP (1983) Molecular genetics, pseudogenetics, and clin-
ical neurology. The Robert Wartenberg lecture. Neurology 33:
1179–1195
Schaefer AM, Taylor RW, Turnbull DM, Chinnery PF (2004) The epide-
miology of mitochondrial disorders–past, present and future.
Biochim Biophys Acta 1659:115–120
Shoffner JM, Lott MT, Voljavec AS, Soueidan SA, Costigan DA,Wallace
DC (1989) Spontaneous Kearns-Sayre/chronic external
J Inherit Metab Dis
ophthalmoplegia plus syndrome associated with a mitochondrial
DNA deletion: a slip-replication model and metabolic therapy.
Proc Natl Acad Sci U S A 86:7952–7956
Skladal D, Halliday J, Thorburn DR (2003)Minimum birth prevalence of
mitochondrial respiratory chain disorders in children. Brain 126:
1905–1912
van Straaten HL, van Tintelen JP, Trijbels JM et al (2005) Neonatal lactic
acidosis, complex I/IV deficiency, and fetal cerebral disruption.
Neuropediatrics 36:193–199
Yamashita S, Nishino I, Nonaka I, Goto Y (2008) Genotype and pheno-
type analyses in 136 patients with single large-scale mitochondrial
DNA deletions. J Hum Genet 53:598–606
J Inherit Metab Dis
